drug
SYNJARDY
Marketedupdated 4mo agoby Boehringer Ingelheim Corp
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 6- tagApproval70 co-mentions · 35 sources
- drugTRIJARDY XR35 co-mentions · 35 sources
- companyBoehringer Ingelheim Corp35 co-mentions · 35 sources
- tagSmall Molecule35 co-mentions · 35 sources
- drugSYNJARDY XR15 co-mentions · 15 sources
- drug(empagliflozin + metformin hydrochloride ER)15 co-mentions · 15 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 37 investigational indications.
indications
investigational
Type 2 Diabetes
all catalysts(47)
approval · 46
Aug 1, 2014
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Jun 26, 2015
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Jun 26, 2015
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Jun 26, 2015
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Aug 26, 2015
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Dec 4, 2015
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Dec 4, 2015
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Jan 12, 2016
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Jan 21, 2016
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Feb 5, 2016
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Mar 18, 2016
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Apr 15, 2016
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
May 6, 2016
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Jul 8, 2016
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Jul 8, 2016
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Jul 8, 2016
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Jul 8, 2016
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Dec 2, 2016
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Dec 23, 2016
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Dec 13, 2017
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Dec 13, 2017
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Oct 26, 2018
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Oct 26, 2018
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Dec 21, 2018
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Jan 24, 2020
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Jan 24, 2020
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Jun 11, 2021
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Jun 11, 2021
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Jun 11, 2021
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Jun 11, 2021
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Aug 18, 2021
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Feb 24, 2022
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Mar 21, 2022
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Mar 21, 2022
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Oct 13, 2022
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Oct 13, 2022
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Feb 6, 2023
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Jun 20, 2023
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Jun 20, 2023
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Jun 20, 2023
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Sep 12, 2023
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Sep 21, 2023
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Oct 30, 2023
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Mar 7, 2025
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Oct 24, 2025
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Oct 24, 2025
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Trials studying SYNJARDY
- phase3A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
- phase2A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
- phase2Empagliflozin in Patients With Cirrhosis and Ascites
- phase3EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
- phase3A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
- phase4Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2
- phase2A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- N/ACLINICAL STUDY TO DETERMINE BIOEQUIVALENCE BETWEEN TWO ORAL MEDICATIONS OF EMPAGLIFLOZIN/METFORMIN IN 5 mg / 850 mg TABLETS UNDER FED CONDITIONS.
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 21, 2026
16 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (147)
- Dec 11, 2034patentUS 9949998*PED
- Dec 11, 2034patentUS 9949998*PED
- Nov 17, 2034patentUS 9949997*PED
- Nov 17, 2034patentUS 9949997*PED
- Nov 17, 2034patentUS 9949997*PED
- Nov 17, 2034patentUS 9949997*PED
- Nov 17, 2034patentUS 9949997*PED
- Nov 17, 2034patentUS 9949997*PED
- Oct 3, 2034patentUS 10258637*PED
- Oct 3, 2034patentUS 10258637*PED
- Oct 3, 2034patentUS 10258637*PED
- Oct 3, 2034patentUS 10258637*PED
- Oct 3, 2034patentUS 10258637*PED
- Oct 3, 2034patentUS 10258637*PED
- Oct 3, 2034patentUS 11090323*PED
- Oct 3, 2034patentUS 11090323*PED
- Oct 3, 2034patentUS 11090323*PED
- Oct 3, 2034patentUS 11090323*PED
- Oct 3, 2034patentUS 11090323*PED
- Oct 3, 2034patentUS 11090323*PED
- Oct 3, 2034patentUS 11813275*PED
- Oct 3, 2034patentUS 11813275*PED
- Oct 3, 2034patentUS 11813275*PED
- Oct 3, 2034patentUS 11833166*PED
- Oct 3, 2034patentUS 11833166*PED
- Oct 3, 2034patentUS 11833166*PED
- Oct 3, 2034patentUS 11833166*PED
- Oct 3, 2034patentUS 11833166*PED
- Oct 3, 2034patentUS 11833166*PED
- Oct 3, 2034patentUS 12433906*PED
- Oct 3, 2034patentUS 12433906*PED
- Oct 3, 2034patentUS 12433906*PED
- Oct 3, 2034patentUS 12433906*PED
- Oct 3, 2034patentUS 12433906*PED
- Oct 3, 2034patentUS 12433906*PED
- Jun 11, 2034method-of-use (U-2290)US 9949998
- Jun 11, 2034method-of-use (U-2290)US 9949998
- May 17, 2034method-of-use (U-2292)US 9949997
- May 17, 2034method-of-use (U-3199)US 9949997
- May 17, 2034method-of-use (U-3533)US 9949997
- May 17, 2034method-of-use (U-3533)US 9949997
- May 17, 2034method-of-use (U-3533)US 9949997
- May 17, 2034method-of-use (U-3533)US 9949997
- Apr 3, 2034method-of-use (U-2290)US 10258637
- Apr 3, 2034method-of-use (U-2290)US 10258637
- Apr 3, 2034method-of-use (U-2290)US 10258637
- Apr 3, 2034method-of-use (U-2290)US 10258637
- Apr 3, 2034method-of-use (U-2290)US 10258637
- Apr 3, 2034method-of-use (U-2290)US 10258637
- Apr 3, 2034method-of-use (U-3191)US 11090323
- Apr 3, 2034method-of-use (U-3191)US 11090323
- Apr 3, 2034method-of-use (U-3193)US 11090323
- Apr 3, 2034method-of-use (U-3193)US 11090323
- Apr 3, 2034method-of-use (U-3193)US 11090323
- Apr 3, 2034method-of-use (U-3193)US 11090323
- Apr 3, 2034method-of-use (U-4154)US 11666590
- Apr 3, 2034method-of-use (U-4154)US 11666590
- Apr 3, 2034method-of-use (U-3691)US 11666590
- Apr 3, 2034method-of-use (U-4154)US 11666590
- Apr 3, 2034method-of-use (U-4154)US 11666590
- Apr 3, 2034method-of-use (U-3759)US 11813275
- Apr 3, 2034method-of-use (U-3759)US 11813275
- Apr 3, 2034method-of-use (U-3760)US 11813275
- Apr 3, 2034method-of-use (U-3776)US 11833166
- Apr 3, 2034method-of-use (U-3777)US 11833166
- Apr 3, 2034method-of-use (U-3776)US 11833166
- Apr 3, 2034method-of-use (U-3777)US 11833166
- Apr 3, 2034method-of-use (U-3776)US 11833166
- Apr 3, 2034method-of-use (U-3776)US 11833166
- Apr 3, 2034method-of-use (U-4171)US 12263153
- Apr 3, 2034method-of-use (U-4154)US 12263153
- Apr 3, 2034method-of-use (U-4154)US 12263153
- Apr 3, 2034method-of-use (U-4154)US 12263153
- Apr 3, 2034method-of-use (U-4154)US 12263153
- Apr 3, 2034method-of-use (U-4171)US 12263153
- Apr 3, 2034method-of-use (U-4287)US 12427162
- Apr 3, 2034method-of-use (U-4287)US 12427162
- Apr 3, 2034method-of-use (U-4287)US 12427162
- Apr 3, 2034method-of-use (U-4287)US 12427162
- Apr 3, 2034method-of-use (U-4287)US 12427162
- Apr 3, 2034method-of-use (U-4287)US 12427162
- Apr 3, 2034method-of-use (U-4296)US 12433906
- Apr 3, 2034method-of-use (U-4296)US 12433906
- Apr 3, 2034method-of-use (U-4296)US 12433906
- Apr 3, 2034method-of-use (U-4296)US 12433906
- Apr 3, 2034method-of-use (U-4296)US 12433906
- Apr 3, 2034method-of-use (U-4296)US 12433906
- Oct 22, 2033patentUS 12527810*PED
- Oct 22, 2033patentUS 12527810*PED
- Oct 22, 2033patentUS 12527810*PED
- Oct 22, 2033patentUS 12527810*PED
- Oct 22, 2033patentUS 12527810*PED
- Oct 22, 2033patentUS 12527810*PED
- Apr 22, 2033method-of-use (U-4403)US 12527810
- Apr 22, 2033method-of-use (U-4403)US 12527810
- Apr 22, 2033method-of-use (U-4403)US 12527810
- Apr 22, 2033method-of-use (U-4403)US 12527810
- Apr 22, 2033method-of-use (U-4403)US 12527810
- Apr 22, 2033method-of-use (U-4403)US 12527810
- Mar 30, 2031patentUS 10610489*PED4.6y
- Mar 30, 2031patentUS 10610489*PED4.6y
- Mar 30, 2031patentUS 10610489*PED4.6y
- Mar 30, 2031patentUS 10610489*PED4.6y
- Sep 30, 2030formulationUS 106104894.1y
- Sep 30, 2030formulationUS 106104894.1y
- Sep 30, 2030formulationUS 106104894.1y
- Sep 30, 2030formulationUS 106104894.1y
- Aug 11, 2030patentUS 12115179*PED3.9y
- Aug 11, 2030patentUS 12115179*PED3.9y
- Aug 11, 2030patentUS 12115179*PED3.9y
- Aug 11, 2030patentUS 12115179*PED3.9y
- Aug 11, 2030patentUS 12115179*PED3.9y
- Aug 11, 2030patentUS 12115179*PED3.9y
- Apr 14, 2030patentUS 8551957*PED3.6y
- Apr 14, 2030patentUS 8551957*PED3.6y
- Feb 11, 2030method-of-use (U-4023)US 121151793.4y
- Feb 11, 2030method-of-use (U-4023)US 121151793.4y
- Feb 11, 2030method-of-use (U-4023)US 121151793.4y
- Feb 11, 2030method-of-use (U-4023)US 121151793.4y
- Feb 11, 2030method-of-use (U-4023)US 121151793.4y
- Feb 11, 2030method-of-use (U-4023)US 121151793.4y
- Oct 14, 2029method-of-use (U-1651)US 85519573.1y
- Oct 14, 2029method-of-use (U-1651)US 85519573.1y
- Feb 1, 2029patentUS 7579449*PED2.4y
- Feb 1, 2029patentUS 7579449*PED2.4y
- Feb 1, 2029patentUS 7579449*PED2.4y
- Feb 1, 2029patentUS 7579449*PED2.4y
- Feb 1, 2029patentUS 7579449*PED2.4y
- Feb 1, 2029patentUS 7579449*PED2.4y
- Aug 1, 2028compositionUS 75794491.9y
- Aug 1, 2028compositionUS 75794491.9y
- Aug 1, 2028compositionUS 75794491.9y
- Aug 1, 2028compositionUS 75794491.9y
- Aug 1, 2028compositionUS 75794491.9y
- Aug 1, 2028compositionUS 75794491.9y
- Oct 15, 2027patentUS 7713938*PED1.1y
- Oct 15, 2027patentUS 7713938*PED1.1y
- Oct 15, 2027patentUS 7713938*PED1.1y
- Oct 15, 2027patentUS 7713938*PED1.1y
- Oct 15, 2027patentUS 7713938*PED1.1y
- Oct 15, 2027patentUS 7713938*PED1.1y
- Apr 15, 2027compositionUS 7713938222d
- Apr 15, 2027compositionUS 7713938222d
- Apr 15, 2027compositionUS 7713938222d
- Apr 15, 2027compositionUS 7713938222d
- Apr 15, 2027compositionUS 7713938222d
- Apr 15, 2027compositionUS 7713938222d
FDA exclusivities (13)
- Dec 20, 2026PEDPediatric (6mo bonus)106d
- Dec 20, 2026PEDPediatric (6mo bonus)106d
- Dec 20, 2026PEDPediatric (6mo bonus)106d
- Dec 20, 2026PEDPediatric (6mo bonus)106d
- Dec 20, 2026PEDPediatric (6mo bonus)106d
- Dec 20, 2026PEDPediatric (6mo bonus)106d
- Sep 21, 2026I-922Indication (3y)16d
- Jun 20, 2026NPPNew Product (3y)
- Jun 20, 2026NPPNew Product (3y)
- Jun 20, 2026NPPNew Product (3y)
- Jun 20, 2026NPPNew Product (3y)
- Jun 20, 2026NPPNew Product (3y)
- Jun 20, 2026NPPNew Product (3y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 35m ago
Found something off?
comments(0)
5-min edit window · permanent after that